Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ofgem mulls rejection of National Grid JV penalty exemption request

(Sharecast News) - Britain's energy regulator Ofgem on Thursday said it was considering whether to reject a delay penalty exemption request for an electricity transmission joint venture between National Grid and SP Transmission. The Eastern Green Link 1 project, being constructed by Iberdrola's Scottish Power Energy Networks and National Grid Electricity Transmission, will build subsea and underground cables between Scotland and north-east England.

In a statement, Ofgem said the joint venture had asked for a 480-day exemption from penalties related to project completion delays, due to global supply chain issues and capacity shortages.

"We do not consider that the joint venture has demonstrated that there has been unavailability of equipment or capacity globally in supply chain," Ofgem said.

"The evidence provided by the JV, and our assessment of it, suggests that an 'error or failure on the licensee's part' as a result of its procurement strategy may have caused the delay. Further evidence provided by the JV also points to a misunderstanding of consenting requirements by one of its suppliers, which we are concerned may have caused the delay to project timescales."

Meanwhile, National Grid in a separate announcement, said the group was trading in line with expectations, consistent with guidance provided at half-year results.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.